Clin Mol Hepatol.
2025 Jan;31(1):e44-e47. 10.3350/cmh.2024.0781.
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
- Affiliations
-
- 1Department of Liver Surgery, Peking Union Medical College Hospital, PUMC, and Chinese Academy of Medical Sciences, Beijing, P. R. China
- 2SCG Cell Therapy Pte. Ltd., Singapore, Singapore
- 3Institute of Virology, School of Medicine, Technical University of Munich / Helmholtz Munich, Munich, Germany
- KMID: 2563455
- DOI: http://doi.org/10.3350/cmh.2024.0781
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
- Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
- Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting
- Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
- Prevalence of the Hepatitis B Surface Antigen in Various Liver Diseases among Koreans Demonstrated by Orcein Staining of 614 Biopsies
